Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced it will release its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time on the same day.
Investors can access the conference call through a webcast on Regeneron's investor relations website. For telephone participation, advance registration is required through a provided link, after which participants will receive confirmation emails with access details. A replay and transcript will be available on the company's website for at least 30 days following the call.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha annunciato che rilascerà i risultati finanziari e operativi del quarto trimestre e dell'intero anno 2024 martedì 4 febbraio 2025, prima dell'apertura dei mercati statunitensi. L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta alle 8:30 ora orientale dello stesso giorno.
Gli investitori possono accedere alla conferenza telefonica tramite una trasmissione in diretta sul sito delle relazioni con gli investitori di Regeneron. Per partecipare telefonicamente, è necessaria una registrazione anticipata attraverso un link fornito, dopo la quale i partecipanti riceveranno email di conferma con i dettagli di accesso. Una registrazione e la trascrizione saranno disponibili sul sito dell'azienda per almeno 30 giorni dopo la chiamata.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha anunciado que publicará sus resultados financieros y operativos del cuarto trimestre y del año completo 2024 el martes 4 de febrero de 2025, antes de la apertura de los mercados de EE. UU. La compañía llevará a cabo una conferencia telefónica y una transmisión web a las 8:30 AM, hora del este, el mismo día.
Los inversores pueden acceder a la conferencia telefónica a través de una transmisión en vivo en el sitio web de relaciones con inversores de Regeneron. Para participar por teléfono, se requiere una inscripción previa a través de un enlace proporcionado, después de lo cual los participantes recibirán correos electrónicos de confirmación con los detalles de acceso. Una grabación y una transcripción estarán disponibles en el sitio web de la empresa durante al menos 30 días después de la llamada.
레제너론 제약 (NASDAQ: REGN)은 2024년 4분기 및 전체 연도 재무 및 운영 결과를 2025년 2월 4일 화요일에 발표할 예정이며, 이는 미국 시장 개장 전에 이루어질 것입니다. 회사는 같은 날 오전 8시 30분 (동부 표준시)에 전화 회의와 웹캐스트를 개최합니다.
투자자들은 레제너온의 투자자 관계 웹사이트를 통해 웹캐스트를 통해 전화 회의에 접속할 수 있습니다. 전화 참여를 원할 경우, 제공된 링크를 통해 사전 등록이 필요하며, 이후 참여자들은 접근 세부 사항이 포함된 확인 이메일을 받게 됩니다. 회의 후에는 회사 웹사이트에서 최소 30일 동안 녹음 및 대본을 이용할 수 있습니다.
Regeneron Pharmaceuticals (NASDAQ: REGN) a annoncé qu'elle publiera ses résultats financiers et opérationnels pour le quatrième trimestre et l'année complète 2024 le Mardi 4 février 2025, avant l'ouverture des marchés américains. L'entreprise organisera une conférence téléphonique et un webinaire à 8h30, heure de l'Est, le même jour.
Les investisseurs peuvent accéder à la conférence téléphonique via un webinaire sur le site Web des relations investisseurs de Regeneron. Pour participer par téléphone, une inscription préalable est requise par le biais d'un lien fourni, après quoi les participants recevront des e-mails de confirmation avec les détails d'accès. Un enregistrement et un procès-verbal seront disponibles sur le site de l'entreprise pendant au moins 30 jours après l'appel.
Regeneron Pharmaceuticals (NASDAQ: REGN) hat angekündigt, dass die finanziellen und betrieblichen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 am Dienstag, den 4. Februar 2025 vor der Eröffnung der US-Märkte veröffentlicht werden. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten.
Investoren können über einen Webcast auf der Investoren-Relations-Website von Regeneron auf die Telefonkonferenz zugreifen. Für die telefonische Teilnahme ist eine vorherige Registrierung über einen bereitgestellten Link erforderlich, nach der die Teilnehmer eine Bestätigungs-E-Mail mit den Zugangsdaten erhalten. Eine Aufzeichnung und ein Transkript werden für mindestens 30 Tage nach dem Anruf auf der Website des Unternehmens verfügbar sein.
- None.
- None.
TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
| Contact Information: | |
| Investor Relations | Corporate Communications |
| Ryan Crowe | Christina Chan |
| 914.847.8790 | 914.847.8827 |
| ryan.crowe@regeneron.com | christina.chan@regeneron.com |
FAQ
When will Regeneron (REGN) report Q4 and full year 2024 earnings?
What time is Regeneron's (REGN) Q4 2024 earnings call?
How can investors access Regeneron's (REGN) Q4 2024 earnings call?
How long will Regeneron's (REGN) Q4 2024 earnings call replay be available?
